31 March 2016 - The Transparency Commission will consider the reimbursement of pertuzumab (Perjeta), lixisenatide (Lyxumia), ezetimibe (Ezetrol) and secukinumab (Cosentyx).  The Commission will also review the SMR & ASMR of a number of reimbursed medicines.

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-03/ordre_du_jour_ct_06042016.pdf [French]